Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV

作者：Andrew W. Hahn, S.A. Ruderman, Robin M. Nance, Bridget M. Whitney, Sherif Eltonsy, Lara Haidar, Lydia N. Drumright, Jimmy Ma, Kenneth H. Mayer, Sonia Napravnik, Joe Eron, K.A. Christopoulos, Laura Bamford, E.R Cachay, George A Yendewa, A Pettit, Michael S. Saag, Susan L. Heath, Richard D. Moore, Jeanne Keruly, D.S. Batey, Geetanjali Chander, M.M Kitahata, Joseph A. Delaney, H.M Crane, R.J Fredericksen · 发表于：Diabetes Care · 年份：2025 · DOI：10.2337/dc25-0236 · 被引用次数：2 · 研究领域：HIV-related health complications and treatments、HIV/AIDS Research and Interventions、HIV/AIDS drug development and treatment

OBJECTIVE: To evaluate semaglutide use among people with HIV (PWH) with medical indications by race and ethnicity. RESEARCH DESIGN AND METHODS: We identified PWH in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort at nine sites eligible for semaglutide therapy between 2019 and 2023. Semaglutide eligibility was based on BMI ≥30 or HbA1c ≥6.5. We evaluated differences in semaglutide receipt among eligible PWH by race and ethnicity using relative risk regression adjusted for demographic characteristics. RESULTS: Among 11,617 eligible PWH, 774 (6.7%) received semaglutide (92% eligible by BMI ≥30, 62% by HbA1c ≥6.5, and 54% by both criteria). Eligible Black PWH were 20% less likely to receive semaglutide versus White PWH (prevalence ratio [PR] 0.80, 95% CI 0.67-0.95). The lower rate of semaglutide for Black (PR 0.66, 95% CI 0.53-0.83) and Hispanic PWH (PR 0.70, 95% CI 0.53-0.93) was more pronounced among those with higher HbA1c (≥8.0). CONCLUSIONS: We describe inequitable semaglutide use among PWH, with lower initiation rates in eligible Black PWH.